Results highlight the heterogeneity of ARSB alleles, with most unique variants (59.5%) identified as missense and 31.7% of unique alleles appearing once. Only 18% of distinct variants were previously recorded in public databases with supporting evidence and clinical significance. ACMG recommends publishing clinical and biochemical data that accurately characterize pathogenicity of new variants in association with reporting specific alleles. Variants analyzed were sent to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), and MPS VI locus-specific database (http://mps6-database.org) where they will be available. High clinical suspicion coupled with diagnostic testing for deficient ASB activity and timely submission and classification of ARSB variants with biochemical and clinical data in public databases is essential for timely diagnosis of MPS VI.
. Importantly, disease prevalence is likely underestimated in all populations since these epidemiological studies generally rely on clinical identification of disease rather than prenatal or newborn screening (Valayannopoulos et al., 2010) .
MPS VI is clinically heterogeneous. Age of onset, rate of disease progression, and clinical manifestations vary widely among individuals. MPS VI can manifest with growth retardation/short stature, coarse facial features, joint stiffness, dysostosis multiplex, hepatosplenomegaly, corneal clouding, macrocephaly, hearing loss, and cardiac and respiratory compromise. Unlike many other lysosomal storage disorders (LSDs), mental development is generally normal, although other symptoms (such as hearing loss) may partially cause developmental delay in some individuals. MPS VI, like other LSDs, is progressive in nature. Untreated patients will continue to deteriorate as GAGs further accumulate within the cell (Jurecka et al., 2011b; Vairo et al., 2015; Valayannopoulos et al., 2010; Wang et al., 2011) .
Historically, individuals with MPS VI have been classified into severity groups based on factors such as age of onset, height, and urinary GAG level. Patients with the classical form of MPS VI (sometimes referred to as severe or rapidly progressing) generally present within the first 3 years of life and display elevated urinary GAG levels (generally >100 g/mg creatinine). In contrast, patients with non-classical MPS VI (sometimes referred to as atypical, attenuated, or slowly progressing) present later in life with more subtle disease manifestations, and may demonstrate slightly elevated (generally <100 g/mg creatinine) or near normal urinary GAG levels (Vairo et al., 2015; Valayannopoulos et al., 2010) . Intermediate forms are also observed.
Fibroblasts and leukocytes of individuals with MPS VI demonstrate absent or reduced ASB enzyme activity compared with healthy controls (Valayannopoulos et al., 2010) . In addition, a non-classical "cardiac phenotype" has been described in some patients with MPS VI.
This form manifests later in adulthood with primarily cardiac features such as valvular disease, cardiomyopathy, and/or acute heart failure, although other symptoms (such as musculoskeletal abnormalities) may also be present (Golda, Jurecka, & Tylki-Szymanska, 2012; Jurecka, Golda, Opoka-Winiarska, Piotrowska, & Tylki-Szymańska, 2011a; Thümler et al., 2012) .
MPS VI is diagnosed through a combination of clinical findings and demonstration of deficient or absent ASB enzyme activity, in conjunction with normal activity of control enzymes, mainly sulfatases, to exclude a multiple sulfatase deficiency. Detection of pathogenic ARSB variants in the proband and in both parents (trio analysis) independently confirms diagnosis and renders genetic counseling possible.
However, this approach may be problematic due to the high proportion of private mutations in MPS VI, thus considering the possibility to identify gene variants that are not yet associated with a clinical phenotype.
Guidelines from the American College of Medical Genetics and
Genomics (ACMG) recommend that gene variants be published in association with clinical classification and validating data (Richards et al., 2015) . In this study, we collected and analyzed all the ARSB variants reported in the literature and in public databases. Of the 201 unique ARSB variants summarized here, only 18% had been previously recorded in public databases (ClinVar, EmvClass, ClinVitae) in association with supporting evidence/clinical classification. The present update illustrates the heterogeneity of alleles associated with MPS VI, the need of a critical evaluation and correct classification of the identified variants, and the lack of prior representation in publicly available variant databases of characterized ARSB alleles.
Variants analyzed in the present paper have been sent to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), where they will be publicly available.
We emphasize the importance to maintain high clinical suspicion during MPS VI diagnosis, as many ARSB alleles identified via molecular testing alone may have yet to be formally classified as MPS VIassociated and cannot be considered diagnostic per se. Timely submission and classification of ARSB variants in public databases, in association with biochemical and clinical data, will help facilitate timely future diagnoses of MPS VI.
METHODOLOGY
To identify all reported pathogenic ARSB variants, a literature search was performed in Embase on October 26, 2017 using the population, intervention and comparators, outcome (PICO) framework where the population was MPS VI (and relevant synonyms) and the outcome was genetic variant (and relevant synonyms); intervention and comparators were not applicable. Results were limited to studies in humans and conference abstracts were excluded. As case reports containing variant data are often not indexed to reflect the presence of this information, a targeted MPS VI case report search was also performed in Embase on September 13, 2017 to supplement the results. The search strategies are described in detail in Supp. Mat. S1. Manual searching of relevant journals not indexed in Embase was also performed. Each identified publication was screened by a single reviewer for information regarding ARSB variants. Reports of individuals with ARSB variants, where variants were reported as linked to MPS VI, were extracted and assessed for redundant reporting to the extent possible.
Public databases were accessed via searches for "ARSB" in ClinVar, EmvClass, ClinVitae, and Human Gene Mutation Database (HGMD) (Hart et al., 2014; Stenson et al., 2003) . Identified variants were compared with those from the literature search.
For the three-dimensional visualization of arylsulfatase B, an image was created using the PyMOL Molecular Graphics System, Version 1.8
Schrödinger, LLC with atomic coordinates from Brookhaven Protein Data Bank accession number 1FSU (Bond et al., 1997 ).
All variants were described according to the NCBI Reference Sequence NM_000046.4 and the corresponding protein sequence NP_000037.2. In cases where the reported variant did not reference a particular sequence, coordinates were mapped to NM_000046.4 [e.g., "deletion of exon 4" to "c.(690+1_691-1)_(898+1_899-1)del"]. Variants cDNA and protein annotations were further checked through "'Name checker'" tool (https://mutalyzer.nl/) according to the HGVS nomenclature v15.11 (https://varnomen.hgvs.org/) and "VariantValidator" tool (https://variantvalidator.org), and corrected if necessary. In case of discrepancies in amino acid sequence impact of coding variants, the variant was simulated and translated in silico using NM_000046.4. All discrepancies and other misreported variants found in our literature analysis were collected in Table 1 . Garcia et al. (2010) For the variants collected, all the evidence available was exploited for variants analysis and clinical classification, according to the approach recommended by ACMG (Richards et al., 2015) . Finally, all variants were submitted to ClinVar database with associated evidence and literature references (ClinVar accession numbers from SCV000802937 to SCV000803138).
TA B L E 1 Summary of misreported variants and corrections

ARSB gene structure
The ARSB gene is located on chromosome 5q13-14 and spans a region , 1997; Peters et al., 1990) .
VARIANTS
Overview and summary statistics
A uniform summary of all ARSB variants identified in individuals with MPS VI was created based on the literature and database searches. Age at diagnosis (reported in 172 individuals) ranged from <1 year to 45 years of age, with a mean of 7.8 years and median of 5.0 years.
Two patients, both with an older affected sibling, were diagnosed at birth (Furujo, Kubo, Kosuga, & Okuyama, 2011; Mendelsohn et al., 2013) . Approximately one-third (31.7%) of unique variants appeared only once in the population assessed, with an additional 28.5% appearing twice.
In agreement with previous reports (Karageorgos et al., 2007b) , most unique variants were missense (59.5%); followed by small deletions (13.5%), nonsense (12.0%), splice site or intronic variants (5.0%), small duplications (3.0%), and large deletions (3.0%) (Figure 1 ).
Stop-loss mutations were identified in 1.0% of variants.
Commonly reported variants occur throughout the length of the ARSB gene, and include missense, nonsense, deletion, and intronic alleles ( Figure 2 ). Only two alleles were reported more than 50 times in our sample taken globally: c.962T>C [p. (Leu321Pro)] and c.454C>T Table 2 ). These alleles are located in exons 5 and 2, respectively.
The most commonly described nonsense allele, c.979C>T
[p.(Arg327*)], was reported 16 times (1.8%) in our sample, and is expected to result in premature truncation of ARSB midway through exon 5. c.979C>T is identified in various populations, including individuals from North and South America, Europe, and Asia, and was detected in a homozygous state in five individuals (5 of 11, 45.5%).
The missense mutation c.284G>A [p.(Arg95Gln) ] is present in six individuals in our sample, but never in the homozygous state. Of note, Arg95 is the final residue making up the N-terminal sulfatase domain (CTPSR sequence), which is conserved in several sulfatases including human arylsulfatase A, human steroid sulfatase, and sea urchin arylsulfatase (Peters et al., 1990) . Individuals with this variant vary in phenotypic severity, presumably based on the allele present in the other ARSB parental allele.
Three large deletions within the alkaline phosphatase-like domain have also been reported. One large deletion that includes exons 2 and 3 was identified in homozygosity in a male Chinese individual with a classical, rapidly progressing MPS VI phenotype (Zheng et al., 2014) ; also a 13.8 kb deletion encompassing exons 2 and 3, whose breakpoints were defined, was reported in homozygosity in a boy with disease onset at 3 years (Ittiwut et al., 2017) . (Ferla et al., 2015) . In only one case, the boundaries were defined (Villani et al., 2010) .
Most common alleles
Of the 12 most commonly reported alleles, 7 of these are missense make up 31.5% of all alleles reported. Together, the three most frequently reported alleles make up 18.5% of all alleles reported (Table 3) .
Importantly, the allele frequency reported here may not represent the real-world distribution of alleles, as well-characterized alleles are less likely to be published and therefore may be underrepresented in the literature.
Geographic distribution
Information regarding ethnic or national origin was available for 406 individuals (85% of sample), and individuals from Africa, Asia, Australia, Europe, North America, and South America were included, although most of them came from the northern hemisphere. Allelic heterogeneity varied among individual populations, although rare or private mutations were prominent in all populations studied. Individuals from Italy, the United States, and Colombia were the most genetically heterogeneous, with the largest proportion of rare or private mutations (≈84% of individuals) in the populations studied ( Figure 3 ).
Turkey was the most heavily represented national origin, with information reported for 55 Turkish individuals (13.5% of total reported).
Of the major populations studied, the and Taiwan (38% of individuals), and was associated with a classical phenotype in these patients.
ASB structure and variants of special interest
Arylsulfatase B includes two domains; a larger N-terminal domain and a smaller C-terminal domain; and reported to function as a monomer (Mathew et al., 2015; McGovern, Vine, Haskins, & Desnick, 1982) .
ASB contains two conserved sulfatase regions near the N-terminal (Bond et al., 1997; Peters et al., 1990) . The active site pocket is located near the surface of the folded enzyme, and consists of Asp53, Asp54, Cys91, Pro93, Ser94, Arg95, Lys145, His147, His242, Asp300, and Lys318. A cluster of conserved cysteine residues is also thought to be required for enzymatic activity (Bond et al., 1997; Brooks et al., 1995) . This is especially true for missense mutations, whose effect on ASB enzyme function may not be immediately apparent (Valayannopoulos et al., 2010) . In addition, residual ASB enzyme activity does not clearly (Karageorgos et al., 2004 (Karageorgos et al., , 2007a Petry et al., 2005) . Leu72 resides in the 3 ′ coil of ASB, and a leucine-to-arginine change is predicted to disrupt formation of this coil and result in severe disturbance of ASB structure (Karageorgos et al., 2007a) . Of note, Leu72 is conserved in certain other sulfatases, including galactose-3-sulfatase (ASA) and N-acetylgalactosamine-6-sulfatase (GALNS) (Bond et al., 1997 (Litjens & Hopwood, 2001 ). p.(Arg160Gln) has been observed in both heterozygous and homozygous states (Kantaputra et al., 2014; Mathew et al., 2015; Villani et al., 2010; Voskoboeva et al., 1994) . The mechanism by which the arginine-to-glutamine alteration contributes to disease is not well understood, as its effect on enzyme structure is predicted to be minimal (Mathew et al., 2015) . However, Arg160 immediately precedes the dipeptide sequence 161-Gly-Phe-162, which is F I G U R E 3 Most common alleles for the 10 most frequent nationalities/ethnic backgrounds reported. The number of times an allele was encountered in a population is shown in parentheses. In grey other variants, reported less or equal to 5 times F I G U R E 4 ASB structure and variants of special interest Three-dimensional structure of mature human ASB protein overlaid with variants of interest. The enzyme active site pocket is indicated by colored space-filling models conserved in arylsulfatases (Peters et al., 1990; Voskoboeva et al., 1994) . Interestingly, wild-type arylsulfatase A (ASA) also contains a glutamine in the position immediately preceding the conserved dipeptide sequence (Peters et al., 1990) .
Of note, a nonsense mutation [p.(Arg160*)] has also been identified at Arg160, and thus Arg160 has been suggested to be a mutational hot spot in the ARSB gene (Kantaputra et al., 2014; Voskoboeva et al., 1994) . Further supporting this idea is the observation that Arg160 mutations have been found in diverse populations and ethnic groups, including patients of Belarusian, German, Indian, Italian, Russian, Spanish, and Taiwanese descent (Garrido et al., 2007; Jurecka et al., 2012a; Kantaputra et al., 2014; Thümler et al., 2012; Voskoboeva et al., 1994 (2002) has demonstrated that the substitution of Tyr210 with cysteine causes impaired protein processing, trafficking, and instability of the mutant ASB protein, ultimately leading to decreased levels of mature, functional protein in lysosomes. Tyr210 is located between the sixth betastrand and fifth alpha-helix of ASB (Saito et al., 2008) . The tyrosineto-cysteine change is predicted to result in a relatively stable enzyme which should retain some enzymatic activity (Saito et al., 2008) . As 2008; Karageorgos et al., 2007b; Petry et al., 2005; Villani et al., 1999) .
Arg315 is predicted to form a salt bridge with Asp466, as well as hydrogen bonds with Gly448 and Glu483 (Garrido et al., 2007; Mathew et al., 2015) . Thus, the arginine-to-glutamine alteration is predicted to hinder both substrate binding and metal ion coordination (Villani et al., 1999) .
Two additional mutations at Arg315 have also been reported-the missense mutation p.(Arg315Pro) and the nonsense mutation p.(Arg315*), which produces a polypeptide roughly one-third the length of wildtype and is predicted to lack enzymatic activity (Di Natale et al., 2008; Ferla et al., 2015; Lin et al., 2008; Mathew et al., 2015; Villani et al., 2010) . Both p. (Arg315Gln) it is believed to be a founder mutation (Kantaputra et al., 2014) .
Interestingly, the c.962T>C mutation is not found in gnomAD (gnomad.broadinstitute.org, accessed October 26, 2017), further supporting the hypothesis that this is primarily a population-specific variant.
Individuals homozygous for p.(Leu321Pro) demonstrated a range of clinical phenotypes, from a classic, rapidly progressing phenotype to a non-classical, slowly progressing phenotype Kantaputra et al., 2014; Zanetti et al., 2014) . Of note, Leu321 is not conserved between the arylsulfatases, and the effect of the p.(Leu321Pro) mutation on the secondary structure of ASB is not known .
c.1197C>G [p.(Phe399Leu)] was observed solely in individuals from
China and Taiwan, and was heavily represented in both populations.
p.(Phe399Leu) was associated with a severe phenotype in homozygous individuals (Lin et al., 2008; Yang, Wu, Lin, & Tsai, 2001; Zheng et al., 2014) . One report suggests that the p.(Phe399Leu) allele may be associated with the polymorphisms c.1072G>A and c.1191G>A, and that these alleles may share a common origin (Lin et al., 2008) .
Homozygosity
Homozygote subjects are particularly represented in the analyzed population of MPS VI patients, 55% of all reported cases. Analysis was associated with a severe phenotype in most subjects (17/21), p.(Arg152Trp) was associated with an attenuated phenotype in almost all subjects (14/15), and p.(Cys192Arg) was associated with an attenuated phenotype in half of the subjects reported (3/6).
Conflicting issues
Two polymorphisms, or benign variants erroneously reported as disease-causing variants, were collected in this review, despite only collecting variants reported as linked to disease. c.1151G>A 
ACMG classification of ARSB variants
A classification of ARSB sequence variants was performed according to ACMG criteria. This analysis evidenced that, for most variants (about 45%), there is not enough evidence in the literature for their classification, and thus they are variants of "uncertain significance." The remaining variants were classified in "likely pathogenic" (37%) and "pathogenic" (16%). One variant (c.113_121del), despite having a frequency < 1% (0.1719%) resulted "benign" using the ACMG approach.
Hence, this in-frame deletion seems to be a polymorphism, if we consider only the South Asian population in which it has a frequency of 1.37%.
These results provide evidence for the need of a deeper analysis of the variants diagnosed in MPS VI patients: this should include both in vitro and in silico analysis. Moreover, specific attention has to be paid to the annotation of the variants: the use of the most updated gene variant nomenclature suggested by HGVS (v15.11) is recommended so as to use shared rules that could unequivocally describe a specific variant with no risk of misreporting.
CLINICAL RELEVANCE
Diagnostic strategies and complications
Mucopolysaccharidoses, including MPS VI, are generally diagnosed by a combination of clinical findings and laboratory tests. Often, the first biochemical test performed upon clinical suspicion of MPS is the analysis of urinary glycosaminoglycans (uGAGs). While commonly used, a positive uGAG test is not sufficient for an MPS diagnosis, and a negative uGAG test is not sufficient to rule out a diagnosis of MPS (Cobos, Steglich, Santer, Lukacs, & Gal, 2015; Vairo et al., 2015) . Additionally, individuals with non-classical MPS VI and/or older individuals with MPS VI may not show strong uGAG elevation (Wood et al., 2012) .
While tandem mass spectrometry-based (MS/MS) testing of uGAGs appears to have increased sensitivity in these individuals, the MS/MS format of the uGAG test is not widely available. Due to the lack of MS/MS availability and the potential to misdiagnose MPS, a lysosomal enzyme panel is often preferable for MPS screening (Wood et al., 2012) .
When clinical suspicion for MPS is high (or after a finding of elevated uGAGs), individuals undergo testing for lysosomal enzyme activity via fibroblasts, leukocytes, or dried blood spots (DBS), which are commonly used due to their low cost, ease of collection, and simple storage requirements (Cobos et al., 2015; Vairo et al., 2015; Wood et al., 2012) . Although enzyme activity varies among individuals (e.g., due to the specific ARSB variant, assay method, etc.), most individuals with MPS VI demonstrate ASB activity <10% of the lower limit of normal level across the disease spectrum (Valayannopoulos et al., 2010) .
A confirmation of MPS VI diagnosis does require the specific pathogenic variants in ARSB to be determined. Moreover, variant identification is beneficial to individuals with MPS VI and their relatives as it can render genetic counseling possible and potentially inform treatment decisions. Although most genotype-phenotype correlations remain uncertain in MPS VI, some variants (e.g., large deletions, nonsense mutations, frameshift, and certain missense mutations) do appear to be correlated with a classic, rapidly progressing phenotype (Karageorgos et al., 2007b) .
Importantly, delays in diagnosis of MPS are quite common, especially in patients with non-classical patterns of disease. These patients may present later in life without the typical physical features of MPS, resulting in a low-clinical suspicion of disease and a delay to diagnosis (Fernández-Marmiesse et al., 2014; Vairo et al., 2015) . In addition, clin- 
Treatment options
The primary goal of therapy in individuals with LSDs is to preserve or restore function by removing excess material accumulated in the lyso- tation has demonstrated effectiveness in some patients (Biffi, 2017; Vairo et al., 2015; Valayannopoulos, 2013) . In addition, novel therapeutic approaches are currently being studied for LSDs including gene therapy, substrate reduction therapy, and chemical chaperone therapy (Macauley, 2016; Rastall & Amalfitano, 2015; Valayannopoulos, 2013 (Giugliani et al., 2014; Harmatz et al., 2006 Harmatz et al., , 2008 Harmatz et al., , 2010 Harmatz et al., , 2014 Naglazyme, BioMarin Pharmaceutical Inc., 2013; Quartel et al., 2018) . As multiple studies have demonstrated that early intervention with ERT (before irreversible complications arise) is beneficial (Furujo et al., 2011; McGill et al., 2010; Meikle & Hopwood, 2003; Muenzer, 2014; Wang et al., 2011) , it is vital that diagnosis be made swiftly and accurately in order to maximize the therapeutic potential of ERT.
FUTURE PROSPECTS
One potential remedy to delayed diagnosis is the wider adaptation of newborn screening, particularly in regions where MPS disorders are common, or prenatal screening when a family history of MPS is known (Wang et al., 2011) . In fact, pilot programs of this nature are already underway in many regions of the world, including parts of Austria, Brazil, Mexico, Spain, Taiwan, and the United States, several of which have proven successful at identifying lysosomal storage disorders (including MPS) in newborns prior to the onset of clinical symptoms (Acosta, Abe-Sandes, Giugliani, & Bittles, 2013; Colón et al., 2017; Hopkins et al., 2015; Lin et al., 2013; Mechtler et al., 2012; NavarreteMartínez et al., 2017) . While these types of screening programs can be somewhat costly and time-consuming, the systematic reporting and classification of alleles has the potential to reduce ethical complications in cases where novel variants with unknown pathogenicity are identified (Wang et al., 2011) .
Another appealing option for diagnosis of MPS is next-generation sequencing (NGS), a platform capable of performing the sequencing of multiple genes in a single reaction. NGS is currently the method of choice for gene panels, whole exome, and whole genome analyses, and is particularly powerful for pathogenic variant identification in disorders such as MPS VI which are rare, clinically heterogeneous, and demonstrate a large proportion of private mutations (Lohmann & Klein, 2014) . For example, whole exome sequencing (WES) was recently demonstrated to successfully diagnose a symptomatic patient with MPS IIIB, revealing compound heterozygous mutations, one of which was novel (Zeng et al., 2017) . Although NGS is more expensive than other commonly used diagnostic techniques, the price has steadily decreased since the advent of NGS and will likely continue to do so, potentially allowing for more widespread use of NGS in practice (Lohmann & Klein 2014; Vairo et al., 2015) . In addition, a genetic diagnosis allows for genetic counseling and rapid treatment initiation, both of which are vital for patients with MPS and their families (Fernández-Marmiesse et al., 2014) . Of note, while NGS is promising, this technique could fail to detect certain pathogenic variants, including complete gene deletions and genetic inversions or rearrangements, potentially leading to false negatives in some cases (Vairo et al., 2015) . 
